Megakaryocytic growth factors: Is there a new approach for management of thrombocytopenia in patients with malignancies?

Leukemia

Volumn 13, Issue , 1999, Pages 14-18

  Hofmann, W K ^a   Ottmann, O G ^a   Hoelzer, D ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

C mpl ligand; Hematopietic growth factors; Megakaryocytic growth factors; Thrombocytopenia; Thrombopoietin

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; HEMOPOIETIC GROWTH FACTOR; LIGAND; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; CARBOPLATIN; HYBRID PROTEIN; MACROGOL DERIVATIVE; POLYETHYLENE GLYCOL RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; POLYETHYLENE GLYCOL-RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT PROTEIN; THROMBOPOIETIN;

ACUTE LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APLASTIC ANEMIA; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CANCER; CELL PROLIFERATION; CONFERENCE PAPER; DOSE RESPONSE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEGAKARYOCYTE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; STEM CELL; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ANIMAL; BLOOD; CELL DIFFERENTIATION; CELL DIVISION; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; MACACA; MOUSE; MULTICENTER STUDY; NEOPLASM; PAPIO; PATHOLOGY; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; REVIEW; STEM CELL MOBILIZATION; PRECURSOR; SHORT SURVEY;

ANEMIA, APLASTIC; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL DIFFERENTIATION; CELL DIVISION; DOUBLE-BLIND METHOD; DRUG EVALUATION, PRECLINICAL; HEMATOPOIETIC STEM CELL MOBILIZATION; HIV INFECTIONS; HUMANS; MACACA MULATTA; MEGAKARYOCYTES; MICE; MULTICENTER STUDIES; MYELODYSPLASTIC SYNDROMES; NEOPLASMS; PAPIO; PLATELET COUNT; POLYETHYLENE GLYCOLS; RADIATION INJURIES, EXPERIMENTAL; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 85047698892     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2401248     Document Type: Article

References (23)

1. Kaushansky K, Nimer SD, Gordon MS, Begley CG. Megakaryocyte growth factors: role in pathophysiology and results of clinical trials. In: JR McArthur, GP Schechter (eds). Hematology 1996: Educational Program, American Society of Hematology. University of Washington School of Medicine, 1996, pp 147-160.
2. Eaton DL, de Sauvage FJ. Thrombopoietin and the humoral regulation of thrombocytopoiesis. Curr Opin Hematol 1995; 2: 167-171.
3. Methia M, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryopoiesis. Blood 1993; 82: 1395-1401.
4. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl deficient mice. Science 1994; 265: 1445-1449.
5. Kuter DJ. In vivo effects of mpl ligand administration and emerging clinical applications for the mpl ligands. Curr Opin Hematol 1997; 4: 163-170.
6. Birkmann J, Oez S, Smetak M, Kaiser G, Kappauf H, Gallmeier WM. Effects of recombinant human thrombopoietin alone and in combination with erythropoietin and early-acting cytokines on human mobilized purified CD34+ progenitor cells cultured in serum-depleted medium. Stem Cells 1997; 15: 18-32.
7. Banu N, Wang JF, Deng B, Groopman JE, Avraham H. Modulation of megakaryocytopoiesis by thrombopoietin: the c-mpl ligand. Blood 1995; 86: 1331-1338.
8. Nichol JL, Hokom MM, Hornkohl A, Sheridan WP, Ohashi H, Kato T, Li YS, Bartley TD, Choi E, Bogenberger J, Skrine JD, Knudten A, Chen J, Trail G, Sleeman L, Cole S, Grampp G, Hunt P. Megakaryocyte growth and development factor. J Clin Invest 1995; 95: 2973-2978.
9. Fiedler PJ, Gurney AL, Stefanich E, Marian M, Moore MW, Carver-Moore K, de Sauvage FJ. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996; 87: 2154-2161.
10. Nichol JL. Serum levels of thrombopoietin in health and diseases. In: DJ Kuter, P Hunt, WSheridan, D Zucker-Franklin (eds). Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical, and Clinical Biology. Human Press: Totowa, 1997, pp 359-375.
11. Ulich TR, del Castillo J, Senaldi G, Kintsler O, Yin S, Kaufman S, Tarpley J, Choi E, Kirley T, Hunt P, Sheridan WP. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood 1996; 87: 5006-5015.
12. Harker LA, Marzec UM, Hunt P, Kelly AB, Tomer A, Cheung E, Hanson SR, Stead RB. Dose-response effects in pegylated megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996; 88: 511-521.
13. Harker LA, Hunt P, Marzec UM, Kelly AB, Tomer A, Hanson SR, Stead RB. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996; 87: 1833-1844.
14. Arnold JT, Daw NC, Stenberg PE, Jayawardene D, Srivastava DK, Jackson CW. A single injection of pegylated murine megakaryocyte growth and development factor (MGDF) into mice is sufficient to produce a profound stimulation of megakaryocyte frequency, size and ploidization. Blood 1997; 89: 823-833.
15. Ulich TR, del Castillo J, Yin S, Swift S, Padilla D, Senaldi G, Bennett L, Shutter J, Bogenberger J, Sun D, Samal B, Shimamoto G, Lee R, Steinbrink R, Boone T, Sheridan WP, Hunt P. Megakaryocyte growth and development factor ameliorates carboplatininduced thrombocytopenia in mice. Blood 1995; 86: 971-976.
16. Farese AM, Hunt P, Grab LB, MacVittle TJ. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia. J Clin Invest 1996; 97: 2145-2151.
17. Basser RL, Rasko JEJ, Clarke K, Cebon J, Green MD, Hussein S, Alt C, Menchaca D, Tomita D, Marty J, Fox RM, Begley CG. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996; 348: 1279-1281.
18. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, Patel S, Reddy SP, Hoots WK, Johnston T, Papadopolous NE, Hittelman WN, Johnston DA, Yang TA, Paton VE, Cohen RL, Hellmann SD, Benjamin RS, Broxmeyer HE. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Int Med 1997; 126: 673-681.
19. Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W, Menchaca D, Tomita D, Ozer H, Harker L. Effects of polyethlene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet count after chemotherapy for lung cancer. New Engl J Med 1997; 336: 404-409.
20. Archimbaud E, Ottmann OG, Liu Yin JA, Lechner K, Dombret H, Sanz MA, Herrmann F, Gruss H, Fenaux P, Ganser A, Heil G, Kanz L, Brugger W, Sims T, Olsen K, Hoelzer D. A randomized, double-blind placebo-controlled study using PEG-rHuMGDF as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia (AML): Early results. Blood 1996; 88 (Suppl. 1): 447a.
21. Rasko JEJ, Basser RL, Boyd J, Mansfield R, O’Malley CJO, Hussein S, Berndt MC, Clarke K, O’Byrne J, Sheridan WP, Grigg AP, Begley CG. Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF. Br J Haematol 1997; 97: 871-880.
22. Basser RL, Rasko JEJ, Clarke K, Cebon J, Green MD, Grigg AP, Zalcberg J, Cohen B, O’Byrne J, Menchaca DM, Fox RM, Begley CG. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997; 89: 3118-3128.
23. Vadhan-Raj S, Patel S, Broxmeyer HE, Bueso-Ramos C, Reddy SP, Papadopolous N, Burgess A, Johnston T, Yang T, Paton V, Hellmann S, Benjamin RS. Phase I-II investigation of recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high-dose chemotherapy (CT) with adriamycin (A) and ifosfamide (I). Blood 1996; 88 (Suppl. 1): 448a.